A last conceivable option is to combine dexosome vaccine with NK-based therapies, such as anti-KIR Ab (anti-killer cell immunoglobulin-like receptor antibody) [203], in order to generate synergistic immunogenic results against NK-dependent cancers. This evidence concerns the gene KIR3DL2 and cancer.